ST. LOUIS, May 8, 2019 /PRNewswire/ — SentiAR, a medical device startup transforming the cardiac ablation procedures, today announced that industry expert Berk Tas has joined the company as CEO and president. Tas brings to SentiAR over a decade in the healthcare medical device industry at both large organizations and startups. Tas has […]
Financial
Radcliffe Group Ltd Appoints Non-Executive Chairman and Chief Scientific Officer
LONDON, May 8, 2019 /PRNewswire/ — Radcliffe Group Ltd (“RG”) announces Professor Andrew Coats (recently Academic Vice President, Monash University and University of Warwick) as Non-Executive Chairman and Dr. Gregory Guillory as Chief Scientific Officer, effective on April 1, 2019. Professor Andrew Coats (top right) is a world-renowned Australian–British academic cardiologist who has a particular interest in the management of heart failure. His research […]
Correvio Reports First Quarter 2019 Financial Results
VANCOUVER, May 8, 2019 /PRNewswire/ – Correvio Pharma Corp. (NASDAQ: CORV / TSX: CORV), a specialty pharmaceutical company focused on commercializing hospital drugs, today reported financial results for its first quarter ended March 31, 2019 and commented on recent accomplishments and plans. “2019 is off to a strong start with first quarter revenues up 16% year-over-year in […]
Verve Therapeutics Founded to Protect Against Heart Disease Launches with $58.5 Million in Series A Funding Led by GV
CAMBRIDGE, Mass.–(BUSINESS WIRE)–Verve Therapeutics, a next-generation cardiovascular company, today announced its launch to discover and develop therapies that safely edit the adult human genome to permanently reduce a person’s risk of coronary artery disease, the most common form of heart disease and the leading cause of death worldwide. Verve brings […]
Endonovo Therapeutics Announces Steven Ford as V.P. Marketing
Los Angeles, CA, May 07, 2019 (GLOBE NEWSWIRE) — Endonovo Therapeutics, Inc. (OTCQB: ENDV), today announced, Steven Ford will be joining the company as Vice President of Marketing. In his position, Mr. Ford will be responsible for growing Endonovo’s pipeline of marketing, content and thought leadership strategies. Mr. Ford has […]
CHF Solutions, Inc. Announces 17 Percent Increase in Revenues for First Quarter 2019 Over Previous Year and Provides Company Update
EDEN PRAIRIE, Minn., May 07, 2019 (GLOBE NEWSWIRE) — CHF Solutions, Inc. (Nasdaq: CHFS) announced today its results for the first quarter ended March 31, 2019, which included the following highlights: Revenue for first quarter ended March 31, 2019 was $1.2 million, an increase of 17 percent compared to the […]
Teleflex Announces Quarterly Dividend
WAYNE, Pa., May 06, 2019 (GLOBE NEWSWIRE) — Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 14, 2019 to shareholders of record at the close of business on […]
LindaCare Builds Powerhouse Remote-Monitoring Team: Two World-Renowned Cardiac Implantable Device Experts Join as Senior Physician Consultants
LEUVEN, Belgium and STAMFORD, Conn., May 6, 2019 /PRNewswire/ — LindaCare, a digital health company specializing in development of remote patient monitoring solutions for chronic disease management, announces at the Heart Rhythm Society Scientific Sessions it has added two of the world’s leading experts in cardiac implantable device management to its Medical Advisory Board: Bruce Wilkoff, MD, […]
Endologix Reports First Quarter 2019 Financial Results
RVINE, Calif.–(BUSINESS WIRE)–Endologix, Inc. (the “Company”) (NASDAQ: ELGX), a developer and marketer of innovative treatments for aortic disorders, today announced financial results for the first quarter ended March 31, 2019. “Our first quarter financial and operational performance provides us with a solid foundation to accomplish our goals for the rest of […]
Hemostemix Announces Convertible Debenture Financing
CALGARY, Alberta, May 03, 2019 (GLOBE NEWSWIRE) — Hemostemix Inc. (“Hemostemix” or the “Company”) (TSX VENTURE: HEM; OTCQB: HMTXF) a biotechnology company focused on developing and commercializing innovative blood-derived stem cell therapies for medical conditions not adequately addressed by current treatments, is pleased to announce that it intends to complete, […]



